시장보고서
상품코드
1763963

OTC 의약품 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측 : 제품별, 제형별, 지역별, 경쟁별(2020-2030년)

Over the Counter Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Dosage Form, By Region and Competition, 2020-2030F

발행일: | 리서치사: TechSci Research | 페이지 정보: 영문 185 Pages | 배송안내 : 2-3일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

OTC 의약품 세계 시장은 2024년에 102억 5,000만 달러로 평가되었으며, 2030년에는 154억 8,000만 달러에 달할 것으로 예측되며, 예측 기간 동안 CAGR 7.31%를 기록할 것으로 예상됩니다.

OTC 의약품은 처방전 없이도 두통, 알레르기, 감기, 소화기 질환, 가벼운 피부 염증 등 일반적인 건강 상태를 관리할 수 있는 편리하고 비용 효율적인 선택입니다. 헬스케어 비용의 증가와 셀프 케어에 대한 관심이 높아지면서 시장 성장의 주요 요인으로 작용하고 있습니다. 소비자들은 전문가 진료의 필요성을 줄여주는 접근성 높은 대체 치료법을 원하고 있으며, 제약사들은 OTC 포트폴리오를 확장하고, 혁신적인 전달 방식과 소비자 교육에 투자하고 있습니다. 그러나 약사 감독 및 규제 강화가 제한적인 지역에서는 과다 복용의 위험과 자가 치료로 인한 합병증 발생 가능성 등 부적절한 사용과 관련된 문제로 인해 시장 확대가 제한되고 있습니다.

시장 개요
예측 기간 2026-2030년
시장 규모 : 2024년 102억 5,000만 달러
시장 규모 : 2030년 154억 8,000만 달러
CAGR : 2025-2030년 7.31%
급성장 부문 기침
최대 시장 북미

시장 촉진요인

헬스케어 산업의 성장

주요 시장 과제

오남용과 자가 치료의 위험

주요 시장 동향

틈새 OTC 부문의 성장

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 COVID-19별 세계의 OTC 의약품 시장에 대한 영향

제5장 세계의 OTC 의약품 시장 전망

  • 시장 규모 및 예측
    • 금액별
  • 시장 점유율과 예측
    • 제품별(기침약, 감기약, 비타민, 미네랄, 보충제(VMS), 진통제, 위장약, 피부과약, 기타)
    • 제형별(정제, 캡슐제, 액제, 크림/로션/연고, 기타)
    • 지역별
    • 기업별(2024)
  • 시장 맵

제6장 북미의 OTC 의약품 시장 전망

  • 시장 규모 및 예측
  • 시장 점유율과 예측
  • 북미 : 국가별 분석
    • 미국
    • 멕시코
    • 캐나다

제7장 유럽의 OTC 의약품 시장 전망

  • 시장 규모 및 예측
  • 시장 점유율과 예측
  • 유럽 : 국가별 분석
    • 프랑스
    • 독일
    • 영국
    • 이탈리아
    • 스페인

제8장 아시아태평양의 OTC 의약품 시장 전망

  • 시장 규모 및 예측
  • 시장 점유율과 예측
  • 아시아태평양 : 국가별 분석
    • 중국
    • 인도
    • 한국
    • 일본
    • 호주

제9장 남미의 OTC 의약품 시장 전망

  • 시장 규모 및 예측
  • 시장 점유율과 예측
  • 남미 : 국가별 분석
    • 브라질
    • 아르헨티나
    • 콜롬비아

제10장 중동 및 아프리카의 OTC 의약품 시장 전망

  • 시장 규모 및 예측
  • 시장 점유율과 예측
  • 중동 및 아프리카 : 국가별 분석
    • 남아프리카공화국
    • 사우디아라비아
    • 아랍에미리트

제11장 시장 역학

  • 성장 촉진요인
  • 과제

제12장 시장 동향과 발전

  • 인수합병
  • 제품 출시
  • 최근 동향

제13장 혼란 : 분쟁, 팬데믹, 무역장벽

제14장 세계의 OTC 의약품 시장 : SWOT 분석

제15장 Porter's Five Forces 분석

  • 업계내 경쟁
  • 신규 참여의 가능성
  • 공급업체의 능력
  • 고객의 능력
  • 대체품의 위협

제16장 경쟁 구도

  • Sanofi SA
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Perrigo Company plc
  • Reckitt Benckiser Group PLC
  • Takeda Pharmaceutical Company Ltd
  • Boehringer Ingelheim International GmbH
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Glenmark Pharmaceuticals Ltd.

제17장 전략적 제안

제18장 조사 회사 소개 및 면책사항

ksm 25.07.18

The Global Over the Counter (OTC) Drugs Market was valued at USD 10.25 Billion in 2024 and is projected to reach USD 15.48 Billion by 2030, registering a CAGR of 7.31% during the forecast period. OTC drugs are a convenient and cost-effective option for managing common health conditions such as headaches, allergies, colds, digestive issues, and minor skin irritations without requiring a prescription. Increasing healthcare costs and a growing inclination toward self-care are major contributors to market growth. Consumers are seeking accessible treatment alternatives that reduce the need for professional consultations, prompting pharmaceutical companies to expand their OTC portfolios and invest in innovative delivery forms and consumer awareness initiatives. However, the market's expansion is tempered by challenges related to improper use, including risks of overuse and potential complications due to self-medication, particularly in regions with limited pharmacist oversight or regulatory enforcement.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 10.25 Billion
Market Size 2030USD 15.48 Billion
CAGR 2025-20307.31%
Fastest Growing SegmentCough
Largest MarketNorth America

Key Market Drivers

Growth in Healthcare Industry

The growing global healthcare industry significantly supports the expansion of the OTC drugs market. Generating over USD 4 trillion annually, the healthcare sector includes highly profitable domains such as pharmaceuticals and biotechnology, which contribute nearly USD 850 billion, and medical technology and diagnostics, accounting for more than USD 400 billion. As healthcare systems become more focused on patient-centered care and cost efficiency, consumers are increasingly turning to OTC medications to manage routine health issues independently. This shift reflects a broader movement toward preventative care, convenience, and greater consumer empowerment, which is driving demand for safe, effective, and readily available OTC treatment options.

Key Market Challenges

Risk of Misuse and Self-Medication

A major concern in the OTC drugs market is the potential for misuse and self-medication. The ease of access to OTC products, while beneficial for minor ailments, can result in unintended health risks when these products are used without adequate medical guidance. Improper dosing, extended use beyond recommended guidelines, or reliance on OTC drugs to manage symptoms of more serious conditions can lead to adverse outcomes. Misuse is particularly common with medications such as analgesics, antacids, and antihistamines, which consumers may not fully understand in terms of contraindications or possible drug interactions. This lack of oversight increases the risk of masking underlying illnesses or exacerbating health issues due to incorrect use.

Key Market Trends

Growth of Niche OTC Segments

The market is witnessing rising interest in niche OTC segments tailored to specific consumer needs and health conditions. As awareness of individual health concerns grows, consumers are seeking more targeted non-prescription solutions that go beyond general-purpose remedies. Categories such as sleep aids, digestive health supplements, women's health products, pediatric treatments, and plant-based options are gaining momentum. These offerings respond to a rising preference for self-managed wellness and preventive care. For instance, sleep aids typically rely on antihistamines like diphenhydramine and doxylamine to reduce wakefulness. Growing attention to conditions such as insomnia, digestive discomfort, and seasonal allergies has fueled demand for customized OTC solutions, encouraging companies to diversify their offerings and explore functional innovations aligned with consumer wellness trends.

Key Market Players

  • Sanofi SA
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Perrigo Company plc
  • Reckitt Benckiser Group PLC
  • Takeda Pharmaceutical Company Ltd
  • Boehringer Ingelheim International GmbH
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Glenmark Pharmaceuticals Ltd.

Report Scope

In this report, the Global Over the Counter (OTC) Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Over the Counter (OTC) Drugs Market, By Product:

  • Cough
  • Cold & Flu
  • Vitamins, Mineral, & Supplements (VMS)
  • Analgesics
  • Gastrointestinal Products
  • Dermatology Products
  • Others

Over the Counter (OTC) Drugs Market, By Dosage Form:

  • Tablets
  • Capsules
  • Liquids & Solutions
  • Cream/Lotion/Ointments
  • Others

Over the Counter (OTC) Drugs Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Over the Counter (OTC) Drugs Market.

Available Customizations

Global Over the Counter (OTC) Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Over the Counter (OTC) Drugs Market

5. Global Over the Counter (OTC) Drugs Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Cough, Cold & Flu, Vitamins, Mineral, & Supplements (VMS), Analgesics, Gastrointestinal Products, Dermatology Products, Others)
    • 5.2.2. By Dosage Form (Tablets, Capsules, Liquids & Solutions, Cream/Lotion/Ointments, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Over the Counter (OTC) Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Dosage Form
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Over the Counter (OTC) Drugs Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Dosage Form
    • 6.3.2. Mexico Over the Counter (OTC) Drugs Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Dosage Form
    • 6.3.3. Canada Over the Counter (OTC) Drugs Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Dosage Form

7. Europe Over the Counter (OTC) Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Dosage Form
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Over the Counter (OTC) Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Dosage Form
    • 7.3.2. Germany Over the Counter (OTC) Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Dosage Form
    • 7.3.3. United Kingdom Over the Counter (OTC) Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Dosage Form
    • 7.3.4. Italy Over the Counter (OTC) Drugs Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Dosage Form
    • 7.3.5. Spain Over the Counter (OTC) Drugs Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Dosage Form

8. Asia Pacific Over the Counter (OTC) Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Dosage Form
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Over the Counter (OTC) Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Dosage Form
    • 8.3.2. India Over the Counter (OTC) Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Dosage Form
    • 8.3.3. South Korea Over the Counter (OTC) Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Dosage Form
    • 8.3.4. Japan Over the Counter (OTC) Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Dosage Form
    • 8.3.5. Australia Over the Counter (OTC) Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Dosage Form

9. South America Over the Counter (OTC) Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Dosage Form
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Over the Counter (OTC) Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Dosage Form
    • 9.3.2. Argentina Over the Counter (OTC) Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Dosage Form
    • 9.3.3. Colombia Over the Counter (OTC) Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Dosage Form

10. Middle East and Africa Over the Counter (OTC) Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Dosage Form
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Over the Counter (OTC) Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Dosage Form
    • 10.3.2. Saudi Arabia Over the Counter (OTC) Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Dosage Form
    • 10.3.3. UAE Over the Counter (OTC) Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Dosage Form

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Disruptions : Conflicts, Pandemics and Trade Barriers

14. Global Over the Counter (OTC) Drugs Market: SWOT Analysis

15. Porters Five Forces Analysis

  • 15.1. Competition in the Industry
  • 15.2. Potential of New Entrants
  • 15.3. Power of Suppliers
  • 15.4. Power of Customers
  • 15.5. Threat of Substitute Products

16. Competitive Landscape

  • 16.1. Sanofi SA
    • 16.1.1. Business Overview
    • 16.1.2. Company Snapshot
    • 16.1.3. Products & Services
    • 16.1.4. Financials (As Reported)
    • 16.1.5. Recent Developments
    • 16.1.6. Key Personnel Details
    • 16.1.7. SWOT Analysis
  • 16.2. Pfizer Inc.
  • 16.3. GlaxoSmithKline plc
  • 16.4. Perrigo Company plc
  • 16.5. Reckitt Benckiser Group PLC
  • 16.6. Takeda Pharmaceutical Company Ltd
  • 16.7. Boehringer Ingelheim International GmbH
  • 16.8. Sun Pharmaceutical Industries Ltd.
  • 16.9. Teva Pharmaceutical Industries Ltd.
  • 16.10. Glenmark Pharmaceuticals Ltd.

17. Strategic Recommendations

18. About Us & Disclaimer

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제